New facility will serve as regional headquarters for Singleron in Asia
Singleron further extends reach outside China and strengthens its expertise in translational and clinical research
Singleron Biotechnologies recently completed its oversubscribed Series B financing, raising close to $100M.
Join our free webinar to get to know our new fully automated tissue dissociation system!
Genomeweb article titled “China's Singleron Biotechnologies Pushes Single-Cell RNA-seq Into Clinical, Translational Studies”
Singleron has raised in A, A1, A2 about $70M in total and introduced prominent investors such as LAV, CDH, ARCH Venture Partners, CDG Capital, and Tencent as new shareholders of the company.
Singleron' products were used in a Covid-study which was recently published in Cell Research on June 16, 2021
Singleron Biotechnologies announced a drug discovery partnership with XtalPi Inc., an AI-powered pharmaceutical technology company.
Singleron Biotechnologies announced its collaboration with Agilent Technologies Inc. (NYSE: A) to accelerate the development and application of single cell sequencing technology.
Singleron completed Series A1 financing of more than $10M, following a recent Series A round that raised $30M
Singleron announced the successful completion of $30 million Series A financing led by Lilly Asia Ventures (LAV)
Report from Wuhan Huoshenshan Hospital to fight against Covid-19
Singleron technologies secured a pre-series A financing worth more than $10M
